CN Patent

CN116003387B — 一种氘代吲唑丙酰胺类化合物、药物组合物和用途

Assigned to Hainan Yaokang Zhongzhi Pharmaceutical Technology Co ltd · Expires 2024-03-26 · 2y expired

What this patent protects

本发明公开了式I所示化合物、或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物，药物组合物和用途。本发明提供的式I所示化合物对CGRP受体具有很好的抑制活性，对与CGRP受体活性异常相关的疾病具有良好的治疗作用。

USPTO Abstract

本发明公开了式I所示化合物、或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物，药物组合物和用途。本发明提供的式I所示化合物对CGRP受体具有很好的抑制活性，对与CGRP受体活性异常相关的疾病具有良好的治疗作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN116003387B
Jurisdiction
CN
Classification
—
Expires
2024-03-26
Drug substance claim
No
Drug product claim
No
Assignee
Hainan Yaokang Zhongzhi Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.